JOSEPH R. GOODWIN, District Judge.
Pending before the court are Plaintiffs' Ancillary Motion for the Court to Declare That O.C.G.A. § 51-12-5.1(e)(2) Is Unconstitutional ("Ancillary Motion") [Docket 454] and Defendant C. R. Bard, Inc.'s Motion to Remit Punitive Damages Award and Amend Judgment ("Motion to Remit") [Docket 452]. For the reasons below, both motions are
This case was the first jury trial within the seven MDLs assigned to me by the Judicial Panel on Multidistrict Litigation concerning the use of transvaginal surgical mesh to treat pelvic organ prolapse ("POP") and stress urinary incontinence ("SUI"). In the seven MDLs, there are more than 70,000 cases currently pending, approximately 10,000 of which are in the C. R. Bard, Inc. ("Bard") MDL, MDL 2187. This particular case concerns Donna Cisson, who was implanted with transvaginal surgical mesh—specifically, the Avaulta Plus Posterior Biosynthetic Support System ("Avaulta Plus") manufactured by Bard to treat POP—in May 2009, and after receiving the implant, she experienced "significant mental and physical pain and suffering." (Compl. [Docket 1] ¶ 10). On March 10, 2011, she and her husband (collectively "the plaintiffs") filed suit against Bard for various causes of action, (id.), and trial began on July 29, 2013.
On August 15, 2013, the jury returned a verdict in favor of Ms. Cisson on her design defect and failure to warn claims.
Bard now moves to remit the punitive damages award from $1,750,000 to $250,000. (Def.'s Mem. in Supp. of Mot. to Remit Punitive Damages Award and Amend J. ("Mem. in Supp. of Remit") [Docket 453], at 1). In addition, the plaintiffs have asked the court to declare Georgia's punitive damages statute, Ga. Code Ann. § 51-12-5.1(e)(2), unconstitutional (Ancillary Mot. [Docket 454]). Georgia's Attorney General, whom I allowed to intervene in this case for the limited purpose of weighing in on this statute, (Order [Docket 475]), has also filed a memorandum in favor of its constitutionality, (see generally Att'y General's Mem. of Law in Opp. to Pls.' Mot. [Docket 476]). My ruling on these matters is set forth below, beginning with a constitutional evaluation of § 51-12-5.1(e)(2) and then turning to the question of remittitur.
Like many states, Georgia has codified its position on the acceptable use of punitive damages in tort actions arising under Georgia law. See generally Ga. Code. Ann. § 51-12-5.1 (2014). As part of its Tort Reform Act of 1987, Georgia added new provisions to its punitive damages scheme that apply specifically to the recovery of punitive damages in products liability cases. In relevant part, § 51-12-5.1(e)(2) provides that
Id. § 51-12-5.1(e)(2). The plaintiffs argue that because § 51-12-5.1(e)(2) requires a prevailing plaintiff in a products liability lawsuit to pay 75% of her punitive damages award to the state, the statute violates the Equal Protection Clause of the Fourteenth Amendment and the Takings Clause of the Fifth Amendment. (Pls.' Mem. in Supp. of Ancillary Mot. [Docket 455], 2-4). Applying the standards set forth below, I
The Equal Protection Clause of the Fourteenth Amendment prohibits a state from "deny[ing] to any person within its jurisdiction the equal protection of the law." U.S. Const. amend. XIV, § 1. The Supreme Court has explained that this clause "is essentially a direction that all persons similarly situated should be treated alike." City of Cleburne v. Cleburne Living Ctr., 473 U.S. 432, 439 (1985). In reviewing an Equal Protection challenge, the court must first ask whether the plaintiff "has been treated differently from others with whom he is similarly situated and that the unequal treatment was the result of intentional or purposeful government decision." Sansotta v. Town of Nags Head, 724 F.3d 533, 542 (4th Cir. 2013) (internal quotations and brackets omitted). Then, the court must examine the disparity "under the requisite level of scrutiny." Id. Both sides agree—as does this court—that rational basis scrutiny applies to the plaintiffs' equal protection challenge to § 51-12-5.1(e)(2). See City of New Orleans v. Dukes, 427 U.S. 297, 303 (1976) (holding that "[u]nless a classification trammels fundamental personal rights or is drawn upon inherently suspect distinctions such as race, religion, or alienage," a court should apply rational basis review). That is, to satisfy the Equal Protection Clause, the statute must be "rationally related to a legitimate state interest." Id.
The Takings Clause of the Fifth Amendment, applicable to the states through the Fourteenth Amendment, Chicago, B. & Q. R. Co. v. Chicago, 166 U.S. 226, 239 (1897), provides that the government shall not take "private property . . . for public use without just compensation." U.S. Const. amend. V. In reviewing a challenge to a statute under the Takings Clause, a court must first "determine whether a constitutionally protected property interest exists." Washlefske v. Winston, 234 F.3d 179, 184 (4th Cir. 2000). To ascertain whether the plaintiff has such an interest in the property at issue, the court must look to state law. Bd. of Regents of State Colls. v. Roth, 408 U.S. 564, 577 (1972) ("Property interests, of course, are not created by the Constitution. Rather they are created and their dimensions are defined by existing rules or understandings that stem from an independent source, such as state law. . . ."). If no cognizable property interest exists, then there is no violation of the Takings Clause. See W. Va. CWP Fund v. Stacy, 671 F.3d 378, 386 (4th Cir. 2011) (finding that the Takings Clause did not apply because the statute at issue did not infringe upon "a specific, identifiable property interest").
Four cases have spoken on the constitutionality of § 51-12-5.1(e)(2). See McBride v. Gen. Motors Corp., 737 F.Supp. 1563 (M.D. Ga. 1990); Mack Trucks, Inc. v. Conkle, 436 S.E.2d 635 (Ga. 1993); State v. Moseley, 436 S.E.2d 632 (Ga. 1993); Ford v. Uniroyal Goodrich Tire Co., 476 S.E.2d 565 (Ga. 1996). Out of the four, only the earliest, McBride, struck down the statute as unconstitutional. 737 F. Supp. at 1579. The three subsequent cases heard by the Supreme Court of Georgia upheld the constitutionality of § 51-12-5.1(e)(2). Taking these cases together—as well as similar cases from around the country—and applying the constitutional standards set forth above, I
As an initial matter, § 51-12-5.1(e)(2) admittedly distinguishes between products liability plaintiffs and other tort plaintiffs, allowing the latter to retain 100% of any punitive damages award, while limiting the former to 25% of the punitive damages award and directing the remaining 75% to the state. The question, therefore, becomes whether this classification is rationally related to a legitimate state interest. In Mack Trucks, Inc., the Supreme Court of Georgia identified the legitimate state interest advanced by § 51-12-5.1(e)(2):
Mack Trucks, Inc., 436 S.E.2d at 638-39 (emphasis added). Put simply, the Supreme Court of Georgia held that § 51-12-5.1(e)(2) furthers the legitimate state interest of deterring conduct that has the potential of harming all citizens, not just the plaintiff, and of compensating the citizenry, as well as the plaintiff, for having to bear that potential risk. Id. The court reaffirmed this holding in two subsequent cases. See Moseley, 436 S.E.2d at 634 (concluding that § 51-12-5.1(e)(2) does not violate equal protection); Ford, 476 S.E.2d at 570 (same).
I must interpret the purpose of § 51-12-5.1(e)(2) as stated by the highest court of Georgia. See CTI/DC, Inc. v. Selective Ins. Co. of Am., 392 F.3d 114, 118 (4th Cir. 2004) ("[The court] must interpret [Maryland] law as it appears that the Maryland Court of Appeals would . . . ."). Accordingly, I do not find the equal protection analysis set forth by the federal court in McBride as persuasive, especially considering that McBride was decided as an issue of first impression. Compare McBride, 737 F. Supp. at 1568 (identifying the state interests advanced by § 51-12-5.1(e)(2) as generating revenue, punishing a manufacturer, and facilitating business operations), with Mack Trucks, Inc., 436 S.E.2d at 639 (rejecting "revenue raising" as the purpose of the statute and instead finding the purpose to be distributing the risk of harm created by products liability among all citizens of the state). The interest set forth in Mack Trucks, Inc. provides a rational basis for allocating the punitive damages award between the citizenry and the plaintiff, and therefore, I uphold § 51-12-5.1(e)(2) against the plaintiffs' equal protection challenge. See F.C.C. v. Beach Commc'ns, Inc., 508 U.S. 307, 313 (1993) ("[A] statutory classification that neither proceeds along suspect lines nor infringes fundamental constitutional rights must be upheld against equal protection challenge if there is any reasonably conceivable state of facts that could provide a rational basis for the classification."); Wilkins v. Gaddy, 734 F.3d 344, 347 (4th Cir. 2013) ("[C]ourts generally accord the legislation a `strong presumption of validity' by applying a rational basis standard of review." (quoting Heller v. Doe, 509 U.S. 312, 319 (1993))). Thus, I
As explained above, a claim under the Takings Clause requires the existence of a "constitutionally protected property interest." Washlefske, 234 F.3d at 184. Georgia has expressly held that "[a] plaintiff has no vested property right in the amount of punitive damages which can be awarded in any case." Mack Trucks, 436 S.E.2d at 639. As a result, the 75% of punitive damages paid to the state under § 51-12-5.1 does not constitute a taking. Id.
The only federal court to confront the issue of whether punitive awards qualify as property for purposes of the Takings Clause has agreed with this conclusion, largely relying on the contingent and discretionary nature of punitive damages awards.
Engquist v. Oregon Dep't of Agric., 478 F.3d 985, 1003-04 (9th Cir. 2007), aff'd sub nom., 553 U.S. 591 (2008) (considering Oregon's split-recovery statute, which provides that sixty percent of any punitive damages award must go to the state's Criminal Injuries Compensation Account).
I agree with the Ninth Circuit's analysis. The plaintiffs have no property interest in the award of punitive damages in this case, and as a result, I
The jury awarded $1,750,000 in punitive damages. (Verdict Form [Docket 406]). This amount is seven times more than the compensatory damages award of $250,000. Bard asks this court to remit the punitive damages amount to $250,000, a one-to-one ratio of punitive damages to compensatory damages, on the theory that the seven-to-one ratio is constitutionally excessive under the facts of this case. (See Mem. in Supp. of Remit [Docket 453], at 1).
The common law mechanism of remittitur is not codified in the Federal Rules of Civil Procedure and is best understood as a variant of Rule 59(a) motion for a new trial. See Cline v. Wal-Mart Stores, Inc., 144 F.3d 294, 305 (4th Cir. 1998) (explaining that remittitur "is used in connection with Fed. R. Civ. P. 59(a)").
Here, Bard challenges the jury's punitive damages award of $1,750,000 on constitutional grounds, asserting that the award violates the Due Process Clause of the Fourteenth Amendment.
Id. at 418 (citing to BMW of N. Am., Inc. v. Gore, 517 U.S. 559, 575 (1996)). If analysis under these guideposts suggests that the award of punitive damages is reasonable and in furtherance of the "legitimate interests in punishing unlawful conduct and deterring its repetition," Gore, 517 U.S. at 568, then there is usually no basis for ordering a remittitur. See, e.g., Saunders v. Branch Banking & Trust Co. of Va., 526 F.3d 142, 155 (4th Cir. 2008) (denying remittitur of the punitive damages award because the Gore guideposts indicated that jury "was not unduly moved by sympathy or bias").
I now discuss each guidepost—reprehensibility, ratio of punitive damages to compensatory damages, and comparable penalties—in light of the facts presented to the jury in this case, ultimately concluding that the punitive damages verdict against Bard passes constitutional muster.
The first guidepost, often considered the most important, directs the court to evaluate "the reprehensibility of the defendant's conduct." Gore, 517 U.S. at 575; see also id. at 575 n.23 ("The flagrancy of the misconduct is thought to be the primary consideration in determining the amount of punitive damages."). In its consideration of the defendant's reprehensibility, a court should consider whether:
Campbell, 538 U.S. at 419. Review of the evidence presented to the jury in this case confirms all but one of these factors.
First, the plaintiffs experienced permanent physical harm, as opposed to economic harm. Indeed, the trial record is replete with descriptions of the pain and physical injury that Ms. Cisson suffered after undergoing implant surgery. (See, e.g., Trial Tr. Aug. 5, 2013 [Docket 373], at 84:1-89:1) (introducing testimony from Ms. Cisson, in which she describes the severe pain she experienced after her mesh implant surgery); Pls.' Ex. 1227A [Docket 418-1], at 15-16 (providing testimony of Ms. Cisson's physician, who opined that Ms. Cisson's vaginal pain following her implantation resulted from extrusion of the mesh)). Moreover, the evidence indicated that this pain is "permanent in nature." (Trial Tr. July 31, 2013 [Docket 367], at 42:24-43:6 (testimony from Dr. Lennox Hoyte)). The permanent physical harm resulting from Bard's conduct has critical weight in the court's evaluation of Bard's reprehensibility. See e.g., Clark v. Chrysler Corp., 436 F.3d 594, 601 (6th Cir. 2006) (expressing that the physical harm resulting from the defendant's conduct "weighs heavily in favor of finding [the defendant's] conduct reprehensible").
Second, the evidence presented at trial demonstrates indifference and reckless disregard of the health and safety of Ms. Cisson. The plaintiffs introduced evidence of both Bard's knowledge of its product's risks and Bard's conscious decision to do nothing in the face of those risks. As I explained in my ruling on Bard's Renewed Motion for Judgment as a Matter of Law, "a reasonable jury could find by clear and convincing evidence that Bard's conduct exhibited an entire want of care raising the presumption of conscious indifference to the consequences." (Mem. Op. & Order [Docket 448], at 24). I then outlined the persuasive evidence, beginning with Bard's knowledge of the polypropylene Material Safety Data Sheet ("MSDS"):
(Id.). In addition, I recalled evidence demonstrating that Bard "understood the dangers of using polypropylene for tissue repair, including a higher risk of erosion and infection; a greater amount of scar tissue formation around the mesh; and a tendency `to unravel, creating a sharp `fishing line' effect, which can slice through the patient's tissue.'" (Id. at 25 (quoting Pls.' Ex. 375)). Yet, Bard did nothing with this knowledge and even overruled suggestions to conduct premarket human trials. (Id. (citing to Pls.' Ex. 1213A)). This analysis, though applied in the context of a motion for judgment as a matter of law, demonstrates Bard's indifference to and conscious disregard of patient health and safety. In addition, the plaintiffs have pointed to several other signs of Bard's conscious indifference that was presented to the jury, such as Bard's knowledge that the arms on the Avaulta Plus could "saw" through tissue. (See Pls.' Resp. in Opp. to Bard's Mot. to Remit ("Resp. to Mot. to Remit") [Docket 460], at 5-7 (citing to Pls.' Ex. 1242A [Docket 419-14])).
In response, Bard contends that its implementation of planning activities, "decades of testing," physician training courses, and post-market surveillance, among other things, mitigated the substantial punitive damages award in this case. (Mem. in Supp. of Remit [Docket 453], at 3). Given the overriding evidence, I disagree. These efforts did nothing to address the specific defects alleged by the plaintiffs, such as the problems caused by polypropylene's reaction with human tissue and the sawing effect created by the arms on the device. Even assuming Bard's testing and surveillance mitigated its responsibility to a slight degree, it is not enough to convince this court that the jury's punitive damages award was "grossly excessive" such that it should be abandoned.
The third factor has no import here. While the financial vulnerability of the plaintiff matters when she has experienced economic harm, see Gore, 517 U.S. at 576 ("To be sure, infliction of economic injury, especially . . . when the target is financially vulnerable, can warrant a substantial penalty."), it has little to no relevance when the plaintiff's injuries are entirely physical. See Clark, 436 F.3d at 604 (concluding that because economic injury is not involved, "wealth is not an appropriate basis" for the punitive damages award). Thus, I do not consider it in assessing the reasonableness of the punitive damages award.
Like the first and second factors, the fourth—whether the conduct involved repeated actions or an isolated incident—also leans against Bard. I find two Fourth Circuit cases instructive on this matter. In Saunders v. Branch Banking & Trust Co. of Virginia, the court considered an award of punitive damages for violations of the Fair Credit Reporting Act. 526 F.3d 142, 145 (4th Cir. 2008). Although the defendant did not engage in "repeated" violations of the Act, the court nevertheless weighed this factor against the defendant because the evidence demonstrated a "longstanding refusal to correct its errors," which, in the court's view, is "more reprehensible [than] a mistake quickly corrected." Id. at 153. The court ultimately upheld the punitive damages amount. Id. at 155. Similarly, in E.E.O.C. v. Federal Express Corp., the Fourth Circuit found that the defendant's "continuing failure and refusal to provide [Americans with Disabilities Act] accommodations" demonstrated repetitive, reprehensible conduct under the fourth factor. 513 F.3d 360, 377 (4th Cir. 2008).
The evidence in the case at bar demonstrates that, like the defendants in the Fourth Circuit cases, Bard had a longstanding and continuous habit of refusing to modify its tortious conduct. In 2007, after becoming aware of the MSDS warning against using polypropylene resin as a permanent medical implant, Bard did not perform new tests on its product or contact the resin manufacturer about the warning, and instead continued to use the resin in its mesh products. (See Trial Tr. Aug. 7, 2013 [Docket 377], at 60:24-62:14 (presenting testimony from Mr. Roger Darois, Vice President of Research and Advanced Technologies for the Davol division of Bard, who confirmed Bard's inaction after discovering the MSDS)). Furthermore, though several physicians and researchers suggested further testing on the Avaulta Plus prior to market, Bard repeatedly declined to perform such tests. (See Pls.' Ex. 1216A [Docket 417-1], at 47:20-48:08 (providing testimony of Dr. Jim Ross, who testified that Bard never carried out his recommendation to conduct randomized controlled trials on women prior to marketing the Avaulta Plus); id. at 119:12-22 (testifying that Bard never did a clinical trial on the Avaulta Plus prior to launch, although Dr. Ross had suggested it)). And finally, with respect to the tests it did perform, Bard disregarded the adverse results, (see, e.g., Pls.' Ex. 1241A [Docket 419-12], at 128:25-131:25 (providing testimony of Mr. Mark Downey, the President of Bard's Davol division, in which he stated that he "didn't do anything" about evaluations from 2008 indicating "the importance of reducing complications," nor did he "inquire" about what should be done about the complication rates)), and declined to inform physicians about the results, (see, e.g., Trial Tr. July 30, 2013 [Docket 365], 105:9-20 (presenting the testimony of Dr. Raybon, Ms. Cisson's physician, who stated that he did not know that Bard's testing demonstrated that the Avaulta Plus did not have "optimal pore size," which could result in the mesh shrinking by 30-50%)). Put simply, the evidence demonstrated that during the market life of the Avaulta Plus, Bard knew about the risks posed by the product and its complication rates, but time and again, Bard did not act to correct the problems. This longstanding and continuous behavior strongly indicates reprehensibility.
Finally, turning to the last factor, the evidence presented to the jury showed that the plaintiffs' harm resulted in part from Bard's deceit. Predicting that resin manufacturers would no longer supply resin to Bard if they discovered the MSDS and Bard's contravention of it, Bard decided to actively conceal its use of the material in pelvic mesh implants. (See Trial Tr. Aug. 7, 2013 [Docket 377], at 64:6-8 ("Q: And you're saying [in this email], `We don't want Phillips to know that we are using this for a medical device.' Correct? A: That's correct."); id. at 70:13-16 (introducing an email that said, "Once again, we need to be certain that we don't contact the resin supplier directly due to the sensitivity of our implant application."); id. at 66:22-67:4 (introducing testimony that one of Bard's suppliers, Shakespeare, refused to supply resin to Bard after obtaining a copy of the MSDS); id. at 69:3-8 (emphasizing the need to keep the medical use of the resin "proprietary" to ensure that suppliers would not "cut off" Bard's supply)). Bard even went as far as to surreptitiously purchase the resin from third parties. (Id. at 69:3-8). This secretive conduct in an effort to sidestep the MSDS warnings suggests reprehensible conduct, weighing against remittitur.
To summarize, four out of the five aggravating factors corroborate the reprehensibility of Bard's conduct, as determined by the jury. With the first and most important guidepost indicating constitutional validity of the punitive damages award, I move to the second guidepost.
The second guidepost requires the court to compare the amount awarded in compensatory damages to the amount awarded in punitive damages. The Supreme Court has consistently "decline[d] to impose a bright-line ratio which a punitive damages award cannot exceed." Campbell, 538 U.S. at 425. The Court has cautioned, however, that "few awards exceeding a single-digit ratio between punitive and compensatory damages, to a significant degree, will satisfy due process." Id. "Reasonable[ness] and proportiona[lity]" are key. Id. Here, the punitive damages award was seven times greater than the compensatory damages award. Given this single-digit multiplier, the court, from the start, can predict that the award most likely comports with due process. See id. ("Single-digit multipliers are more likely to comport with due process, while still achieving the State's goals of deterrence and retribution, than awards with ratios in range of 500 to 1 [or] 145 to 1."); Saunders, 526 F.3d at 154 (describing a punitive damages award within the single-digit ratio as "normal").
Nevertheless, Bard argues that because the award of compensatory damages was "substantial," due process only permits a one-to-one ratio. (Mem. in Supp. of Remit [Docket 453], at 6 (citing to Campbell, 538 U.S. at 428 ("When compensatory damages are substantial, then a lesser ratio, perhaps only equal to compensatory damages, can reach the outermost limit of the due process guarantee."))). The plaintiffs, of course, respond that $250,000 "is not `substantial' under the facts of this case." (Resp. to Mot. to Remit [Docket 460], at 13). I find it difficult, if not impossible, to put a label on this award as "substantial" or "not substantial" when the plaintiffs' injuries were purely physical with no economic or quantifiable components. In Campbell, for instance, the plaintiffs' harm "arose from a transaction in the economic realm, not from some physical assault or trauma," and the Court could easily define the compensatory damages as substantial. 538 U.S. at 426. In contrast, this case concerns pain and physical suffering alone. There is no marketplace where we sell pain and suffering, and as such, measuring the compensatory damages award in this case is akin to placing a value on an arbitrary enterprise. I therefore refuse to quantify the compensatory damages in this case as substantial or not substantial and instead defer to and trust in the jury's valuation of the plaintiffs' injuries and perception of Bard's reprehensibility.
Because the disparity between the punitive damages and compensatory damages does not exceed the acceptable single-digit ratio and reflects the jury's assessment of Bard's reprehensible conduct, I find that the second guidepost weighs in favor of upholding the punitive damages award.
The third guidepost arises from the premise that a punitive damages award "cannot be justified on the ground that it was necessary to deter future misconduct without considering whether less drastic remedies could be expected to achieve that goal." Gore, 517 U.S. at 584. The court must determine whether the punitive damages award "is excessive in light of comparable civil penalties." Clark, 436 F.3d at 607. Unable to identify a comparable civil penalty under Georgia law for the reprehensible conduct at issue, Bard calls upon the federal Safe Medical Devices Act of 1990, which imposes fines against device manufacturers for various violations of federal requirements related to medical devices. See generally 21 U.S.C. § 333(f) (2012). Pursuant to this Act, a device manufacturer is subject to a maximum $1,000,000 civil penalty for failing to comply with certain federal requirements concerning risk evaluation and mitigation, safety labeling, and clinical trials. Id. Bard argues that the punitive damage award "is significantly larger than the maximum civil penalty Congress deemed appropriate for the alleged conduct at issue in this case," and therefore, remittitur is required. (Mem. in Supp. of Remit [Docket 453], at 8).
Bard's reliance on § 333(f) is misplaced. While § 333(f) reprimands manufacturers for violations of the Federal Food, Drug and Cosmetic Act ("FDCA"), such as misbranding, the statute does not provide sanctions for conduct that is not regulated by the FDCA, such as a manufacturer's failure to warn physicians about known risks. Furthermore, the statute does not appear to take into account the consequences of any one violation of the FDCA. And in this case, the jury found that the consequences experienced by Ms. Cisson were severe and permanent. In short, the civil penalty provided under the Safe Medical Devices Act only sanctions one element of tortious conduct—breach—and does not on its face address duty, causation, or injury. I do not regard § 333(f) as a "comparable civil penalty" for purposes of applying the third guidepost, and as a result, the last guidepost does not provide much assistance one way or the other in this matter. See, e.g., Fox v. Encounters Int'l, No. 05-1139, 2006 WL 952317, at *9 (4th Cir. Apr. 13, 2006) (passing over the third guidepost because the civil penalty offered "does not take into consideration the willful and wantonness of Defendants' conduct" and was therefore not comparable to the punitive damages award).
The first and second guideposts, however, demonstrate that there is no basis upon which to order a remittitur. The seven-to-one ratio is both reasonable and proportionate to the amount of harm inflicted upon the plaintiffs, and in light of what the jury found to be reprehensible conduct, the award furthers the dual purposes of punishment and deterrence without entering the "zone of arbitrariness" that would render it unconstitutional. Gore, 517 U.S. at 568.
I do not find Bard's other arguments advanced in support of remittitur persuasive. First, Bard contends that the punitive damages award "is duplicative and without purpose." (Mem. in Supp. of Remit [Docket 453], at 8). The jury instructions confirm, however, that the compensatory damages award did not "contain [a] punitive element," Campbell, 538 U.S. at 426, that could have produced duplicative awards. (Compare Final Jury Instructions [Docket 339], at 21-22 (instructing that compensatory damages "are given as pay or compensation for injury done" and that the jury could consider pain and suffering; anxiety, shock, and worry; and loss of capacity to work or labor), with Trial Tr. Aug. 15, 2013 [Docket 408], at 59:3-7 (instructing the jury to consider Bard's misconduct in awarding punitive damages, including "[t]he nature and egregiousness or reprehensibility of Bard's conduct; the extent and duration of Bard's wrongdoing and the likelihood of its recurrence; [and] the intent of Bard in committing the wrong"), and id. at 59:18-20 (instructing the jury to take into account the purpose of punitive damages)). Bifurcating the liability issue from the punitive damages issue also served to avoid duplicative awards. (See Mem. Op. & Order re: Mots. for Summ. J. [Docket 273], at 19-20 (granting Bard's motion to bifurcate the trial)). Second, Bard maintains that the punitive damages award was improperly based on injuries to nonparties. Aside from recanting the argument that the punitive damages award should only be based on the MSDS—an argument I have already rejected, see supra n.8—Bard offers no support from the transcript or the exhibit record indicating that the jury was privy to the injuries of nonparties in its deliberation.
In conclusion, the Gore guideposts weigh in favor of upholding the jury's punitive damages award, and I therefore
For all the foregoing reasons, I
The court